4-Phenylbutyric Acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Ulobetasol.
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Ulobetasol.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Ulobetasol.
Advertisement
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ulobetasol.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Ulobetasol.
Aldesleukin
Ulobetasol may decrease the antineoplastic activities of Aldesleukin.
Advertisement
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Ulobetasol.
Aloxiprin
The risk or severity of adverse effects can be increased when Aloxiprin is combined with Ulobetasol.
Aluminum
The bioavailability of Ulobetasol can be decreased when combined with Aluminium.
Advertisement
Aluminum Hydroxide
The bioavailability of Ulobetasol can be decreased when combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The bioavailability of Ulobetasol can be decreased when combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The bioavailability of Ulobetasol can be decreased when combined with Almasilate.
Ambenonium
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Ambenonium.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ulobetasol.
Amiodarone
The serum concentration of Ulobetasol can be increased when it is combined with Amiodarone.
Amphotericin B
Ulobetasol may increase the hypokalemic activities of Amphotericin B.
amphotericin B liposomal
Ulobetasol may increase the hypokalemic activities of Amphotericin B.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ulobetasol.
Apalutamide
The serum concentration of Ulobetasol can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Ulobetasol.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Ulobetasol.
Aprepitant
The serum concentration of Ulobetasol can be increased when it is combined with Aprepitant.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ulobetasol.
Atazanavir
The serum concentration of Ulobetasol can be increased when it is combined with Atazanavir.
Atracurium Besylate
Atracurium besylate may increase the adverse neuromuscular activities of Ulobetasol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Ulobetasol.
Azosemide
Ulobetasol may increase the hypokalemic activities of Azosemide.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Ulobetasol.
BCG Vaccine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with BCG vaccine.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Bacillus calmette-guerin substrain tice live antigen.
Bendroflumethiazide
Ulobetasol may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Ulobetasol.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Ulobetasol.
Bismuth Subcitrate
The bioavailability of Ulobetasol can be decreased when combined with Bismuth Subcitrate.
Boceprevir
The serum concentration of Ulobetasol can be increased when it is combined with Boceprevir.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Ulobetasol.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Ulobetasol.
Bumetanide
Ulobetasol may increase the hypokalemic activities of Bumetanide.
Calcitriol
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Ulobetasol.
Calcium Carbonate
The bioavailability of Ulobetasol can be decreased when combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The bioavailability of Ulobetasol can be decreased when combined with Calcium Carbonate.
Capromab Pendetide
Ulobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Carbamazepine
The serum concentration of Ulobetasol can be decreased when it is combined with Carbamazepine.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Ulobetasol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Ulobetasol.
Ceritinib
Ulobetasol may increase the hyperglycemic activities of Ceritinib.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Ulobetasol.
Chlorothiazide
Ulobetasol may increase the hypokalemic activities of Chlorothiazide.
Chlorotrianisene
The serum concentration of Ulobetasol can be increased when it is combined with Chlorotrianisene.
Chlorthalidone
Ulobetasol may increase the hypokalemic activities of Chlorthalidone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ulobetasol.
Cinoxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Cinoxacin.
Clarithromycin
The serum concentration of Ulobetasol can be increased when it is combined with Clarithromycin.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Ulobetasol.
Cobicistat
The serum concentration of Ulobetasol can be increased when it is combined with Cobicistat.
Colesevelam
Colesevelam can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Corticorelin Ovine
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Ulobetasol.
Corticorelin Ovine Triflutate
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Ulobetasol.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Ulobetasol.
Cyclopenthiazide
Ulobetasol may increase the hypokalemic activities of Cyclopenthiazide.
Danazol
Ulobetasol may increase the fluid retaining activities of Danazol.
Darunavir
The serum concentration of Ulobetasol can be increased when it is combined with Darunavir.
Deferasirox
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Deferasirox.
Demecarium
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Demecarium.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Ulobetasol.
Dienestrol
The serum concentration of Ulobetasol can be increased when it is combined with Dienestrol.
Diethylstilbestrol
The serum concentration of Ulobetasol can be increased when it is combined with Diethylstilbestrol.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Ulobetasol.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Ulobetasol.
Distigmine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Distigmine.
Donepezil
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Donepezil.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Ulobetasol.
Echothiophate
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Echothiophate.
Edrophonium
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Edrophonium.
Enoxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Enoxacin.
Enzalutamide
The serum concentration of Ulobetasol can be decreased when it is combined with Enzalutamide.
Equol, (-)-
The serum concentration of Ulobetasol can be increased when it is combined with Equol.
Estradiol
The serum concentration of Ulobetasol can be increased when it is combined with Estradiol.
Estradiol acetate
The serum concentration of Ulobetasol can be increased when it is combined with Estradiol acetate.
Estradiol Cypionate
The serum concentration of Ulobetasol can be increased when it is combined with Estradiol cypionate.
Estradiol Valerate
The serum concentration of Ulobetasol can be increased when it is combined with Estradiol valerate.
Estriol
The serum concentration of Ulobetasol can be increased when it is combined with Estriol.
Estrogens, Conjugated (USP)
The serum concentration of Ulobetasol can be increased when it is combined with Conjugated estrogens.
Estrogens, Esterified (USP)
The serum concentration of Ulobetasol can be increased when it is combined with Estrogens, esterified.
Estrone
The serum concentration of Ulobetasol can be increased when it is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Ulobetasol.
Ethacrynate
Ulobetasol may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Ulobetasol may increase the hypokalemic activities of Etacrynic acid.
Ethinyl Estradiol
The serum concentration of Ulobetasol can be increased when it is combined with Ethinyl Estradiol.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Ulobetasol.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Ulobetasol.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ulobetasol.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ulobetasol.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Ulobetasol.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Ulobetasol.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ulobetasol.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ulobetasol.
Fleroxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Ulobetasol.
Flumequine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Flumequine.
Fluoxymesterone
Ulobetasol may increase the fluid retaining activities of Fluoxymesterone.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ulobetasol.
Fosaprepitant
The serum concentration of Ulobetasol can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Ulobetasol can be decreased when it is combined with Fosphenytoin.
Furosemide
Ulobetasol may increase the hypokalemic activities of Furosemide.
Galantamine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Gallamine Triethiodide.
Gatifloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Gatifloxacin.
Gatifloxacin Anhydrous
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Gatifloxacin.
Gemifloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Gemifloxacin.
Gemifloxacin Mesylate
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Gemifloxacin.
Genistein
The serum concentration of Ulobetasol can be increased when it is combined with Genistein.
Ginkgo biloba extract
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Ginkgo biloba.
Glycerol Phenylbutyrate
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Ulobetasol.
Grepafloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Grepafloxacin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Hepatitis B Vaccine (Recombinant).
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ulobetasol.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ulobetasol.
Hydrochlorothiazide
Ulobetasol may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Ulobetasol may increase the hypokalemic activities of Hydroflumethiazide.
Hydrotalcite
The bioavailability of Ulobetasol can be decreased when combined with Hydrotalcite.
Hypoxis hemerocallidea root extract
The serum concentration of Ulobetasol can be decreased when it is combined with St. John's Wort.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ulobetasol.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Ulobetasol.
Idelalisib
The serum concentration of Ulobetasol can be increased when it is combined with Idelalisib.
Indacaterol
Indacaterol may increase the hypokalemic activities of Ulobetasol.
Indapamide
Ulobetasol may increase the hypokalemic activities of Indapamide.
Indinavir
The serum concentration of Ulobetasol can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Ulobetasol can be increased when it is combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Ulobetasol.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ulobetasol.
Isoflurophate
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Isoflurophate.
Isoniazid
The serum concentration of Isoniazid can be decreased when it is combined with Ulobetasol.
Itraconazole
The serum concentration of Ulobetasol can be increased when it is combined with Itraconazole.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Ulobetasol.
Ketoconazole
The serum concentration of Ulobetasol can be increased when it is combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ulobetasol.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ulobetasol.
Lacidipine
The serum concentration of Lacidipine can be decreased when it is combined with Ulobetasol.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Ulobetasol.
Levofloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Levofloxacin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ulobetasol.
Lopinavir
The serum concentration of Ulobetasol can be increased when it is combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ulobetasol.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Ulobetasol.
Lumacaftor
The serum concentration of Ulobetasol can be decreased when it is combined with Lumacaftor.
Magaldrate
The bioavailability of Ulobetasol can be decreased when combined with Magaldrate.
Magnesium Hydroxide
The bioavailability of Ulobetasol can be decreased when combined with Magnesium hydroxide.
Magnesium Oxide
The bioavailability of Ulobetasol can be decreased when combined with Magnesium oxide.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ulobetasol.
Magnesium Trisilicate
The bioavailability of Ulobetasol can be decreased when combined with Magnesium Trisilicate.
Malathion
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Malathion.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Ulobetasol.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ulobetasol.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ulobetasol.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ulobetasol.
Mefloquine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Mefloquine.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ulobetasol.
Memantine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Memantine.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Ulobetasol.
Mesterolone
Ulobetasol may increase the fluid retaining activities of Mesterolone.
Mestranol
The serum concentration of Ulobetasol can be increased when it is combined with Mestranol.
Methyclothiazide
Ulobetasol may increase the hypokalemic activities of Methyclothiazide.
Methyl Salicylate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ulobetasol.
Methyltestosterone
Ulobetasol may increase the fluid retaining activities of Methyltestosterone.
Metoclopramide
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Metoclopramide.
Metolazone
Ulobetasol may increase the hypokalemic activities of Metolazone.
Mifepristone
The therapeutic efficacy of Ulobetasol can be decreased when used in combination with Mifepristone.
Minaprine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Minaprine.
Mitotane
The serum concentration of Ulobetasol can be decreased when it is combined with Mitotane.
Mivacurium
Mivacurium may increase the adverse neuromuscular activities of Ulobetasol.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ulobetasol.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ulobetasol.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ulobetasol.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ulobetasol.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Ulobetasol.
Nalidixic Acid
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Nalidixic Acid.
Nandrolone
Ulobetasol may increase the fluid retaining activities of Nandrolone.
Nandrolone Decanoate
Ulobetasol may increase the fluid retaining activities of Nandrolone decanoate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Ulobetasol.
Nefazodone
The serum concentration of Ulobetasol can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Ulobetasol can be increased when it is combined with Nelfinavir.
Neostigmine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Neostigmine.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Ulobetasol.
Nevirapine
The serum concentration of Ulobetasol can be decreased when it is combined with Nevirapine.
Nicorandil
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Nicorandil.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ulobetasol.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Ulobetasol.
Norfloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Norfloxacin.
O-PHENANTHROLINE
The risk or severity of adverse effects can be increased when Ulobetasol is combined with 1,10-Phenanthroline.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ulobetasol.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Ulobetasol.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Ulobetasol.
Oxandrolone
Ulobetasol may increase the fluid retaining activities of Oxandrolone.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ulobetasol.
Oxymetholone
Ulobetasol may increase the fluid retaining activities of Oxymetholone.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ulobetasol.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Ulobetasol.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Ulobetasol.
Pefloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Pefloxacin.
Pentobarbital
The serum concentration of Ulobetasol can be decreased when it is combined with Pentobarbital.
Phenobarbital
The serum concentration of Ulobetasol can be decreased when it is combined with Phenobarbital.
Phenylacetic Acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Ulobetasol.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ulobetasol.
Phenylbutyrate
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Ulobetasol.
Phenytoin
The serum concentration of Ulobetasol can be decreased when it is combined with Phenytoin.
Physostigmine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Physostigmine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ulobetasol.
Piretanide
Ulobetasol may increase the hypokalemic activities of Piretanide.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ulobetasol.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Ulobetasol.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Ulobetasol.
Polyestradiol Phosphate
The serum concentration of Ulobetasol can be increased when it is combined with Polyestradiol phosphate.
Polythiazide
Ulobetasol may increase the hypokalemic activities of Polythiazide.
Posaconazole
The serum concentration of Ulobetasol can be increased when it is combined with Posaconazole.
Primidone
The serum concentration of Ulobetasol can be decreased when it is combined with Primidone.
Promestriene
The serum concentration of Ulobetasol can be increased when it is combined with Promestriene.
Pyridostigmine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Pyridostigmine.
Pyridostigmine Bromide
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Pyridostigmine.
Quinestrol
The serum concentration of Ulobetasol can be increased when it is combined with Quinestrol.
Quinethazone
Ulobetasol may increase the hypokalemic activities of Quinethazone.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Rabies virus inactivated antigen, A.
Rapacuronium
Rapacuronium may increase the adverse neuromuscular activities of Ulobetasol.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Ulobetasol.
Rifabutin
The serum concentration of Ulobetasol can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Ulobetasol can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Ulobetasol can be decreased when it is combined with Rifapentine.
Rivastigmine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Rivastigmine.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ulobetasol.
Rosoxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Rosoxacin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Rubella virus vaccine.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Ulobetasol.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ulobetasol.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Ulobetasol.
Saquinavir
The serum concentration of Ulobetasol can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Ulobetasol can be increased when it is combined with Saquinavir.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Ulobetasol.
Sodium Bicarbonate
The bioavailability of Ulobetasol can be decreased when combined with Sodium bicarbonate.
Sparfloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Sparfloxacin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Ulobetasol can be decreased when it is combined with St. John's Wort.
Stanozolol
Ulobetasol may increase the fluid retaining activities of Stanozolol.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ulobetasol.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Ulobetasol.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Ulobetasol.
synthetic conjugated estrogens, A
The serum concentration of Ulobetasol can be increased when it is combined with Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
The serum concentration of Ulobetasol can be increased when it is combined with Synthetic Conjugated Estrogens, B.
Tacrine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Tacrine.
Telaprevir
The serum concentration of Telaprevir can be decreased when it is combined with Ulobetasol.
Telithromycin
The serum concentration of Ulobetasol can be increased when it is combined with Telithromycin.
Temafloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Temafloxacin.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ulobetasol.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ulobetasol.
Testosterone
Ulobetasol may increase the fluid retaining activities of Testosterone.
Testosterone Cypionate
The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Ulobetasol.
Testosterone Enanthate
The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Ulobetasol.
Testosterone Propionate
Ulobetasol may increase the fluid retaining activities of Testosterone propionate.
Testosterone Undecanoate
The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Ulobetasol.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ulobetasol.
Tibolone
The serum concentration of Ulobetasol can be increased when it is combined with Tibolone.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ulobetasol.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Ulobetasol.
Torsemide
Ulobetasol may increase the hypokalemic activities of Torasemide.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Ulobetasol.
Trichlormethiazide
Ulobetasol may increase the hypokalemic activities of Trichlormethiazide.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ulobetasol.
Tromethamine
The bioavailability of Ulobetasol can be decreased when combined with Tromethamine.
Trovafloxacin
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Trovafloxacin.
Tubocurarine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Tubocurarine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Ulobetasol.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Varicella Zoster Vaccine (Live/Attenuated).
Voriconazole
The serum concentration of Ulobetasol can be increased when it is combined with Voriconazole.
Warfarin
Ulobetasol may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Ulobetasol.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Ulobetasol.
